FDA declines to approve Allergan's Esmya

Written by Medical Dialogues Bureau Published On 2018-08-24T09:45:02+05:30 | Updated On 16 Aug 2021 5:36 PM IST

Allergan Plc said U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

The safety concerns raised could impact the company's plan to sell its women's health business.

Earlier this year, regulators in Europe slapped temporary restrictions on the use of the drug, after reports that it was linked to serious liver damage.

AllerganEsmyaFDAFDA declinesliver damagepharmauterine fibroids

Source : REUTERS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here